BioNTech SE Announces Acquisition of CureVac N.V.

BioNTech SE ( (BNTX) ) has issued an update.

On June 12, 2025, BioNTech SE announced a purchase agreement to acquire CureVac N.V. through a public exchange offer, followed by a reorganization to make CureVac a wholly-owned subsidiary. This strategic acquisition aims to consolidate BioNTech’s position in the biotechnology sector by expanding its capabilities and resources, potentially impacting stakeholders by enhancing the company’s market share and operational efficiencies.

The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.

Spark’s Take on BNTX Stock

According to Spark, TipRanks’ AI Analyst, BNTX is a Neutral.

BioNTech’s strong balance sheet and positive technical momentum are offset by profitability challenges and financial losses highlighted in the earnings call. Strategic investments in oncology could drive future growth, but current financial risks weigh on the overall score.

To see Spark’s full report on BNTX stock, click here.

More about BioNTech SE

BioNTech SE is a biotechnology company based in Mainz, Germany, primarily focused on developing and manufacturing immunotherapies for cancer and other serious diseases. The company is known for its work in mRNA-based vaccines, notably its collaboration with Pfizer on the COVID-19 vaccine.

Average Trading Volume: 1,233,776

Technical Sentiment Signal: Buy

Current Market Cap: $25.56B

Find detailed analytics on BNTX stock on TipRanks’ Stock Analysis page.